What is Acorda Therapeutics, Inc. (ACOR)?

Acorda Therapeutics, Inc. (ACOR) is a stock in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry. View full analysis on Stocks360.

What is the current price of ACOR?

The current price of ACOR is $0.66. Prices are updated in real time on Stocks360.

What is ACOR's price-to-earnings (PE) ratio?

ACOR's trailing twelve-month PE ratio is -0.00, based on current price and earnings per share data available on Stocks360.

What is ACOR's market capitalization?

ACOR's market capitalization is $821,028.00, placing it in the small-cap tier.

Acorda Therapeutics, Inc. (ACOR)

Stock analysis · NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

$0.66

Market Cap

$821.03K

PE (TTM)

-0.00

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.46

Day Range

$0.61 – $0.85

52-wk Range

$0.61 – $24.20

Avg Volume

N/A

Volume

321.67K

Acorda Therapeutics, Inc. (ACOR) is a publicly traded company in the Healthcare sector. Latest price: $0.66. Market cap $821.03K. Trailing PE -0.00. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Mar 9, 2023

EPS $11.40 vs est. $-3.00

Beat by $14.40

Proprietary Signals

Signal snapshot temporarily unavailable.

About Acorda Therapeutics, Inc.

Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing treatments for conditions affecting the nervous system, primarily within the United States. Its current product offerings include Ampyra (dalfampridine), an oral medication prescribed to enhance walking ability in individuals with multiple sclerosis (MS). The company also distributes Inbrija in Europe, which is used to manage "OFF" periods experienced by Parkinson's disease patients. Globally, Ampyra is recognized and sold as Fampyra across Europe, Asia, and the Americas. Beyond its existing products, Acorda is actively advancing several experimental therapies: ARCUS for the management of acute migraine attacks, rHIgM22 which has successfully completed Phase I clinical trials for MS, and Cimaglermin alfa, currently being investigated for patients with heart failure. The company holds a licensing and collaborative agreement with Biogen Inc. for the ongoing development and market distribution of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and operates from its headquarters in Ardsley, New York.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.00×
P/S (TTM)	0.01×
P/B	-0.01×
PEG	0.00×
P/FCF (TTM)	-0.06×
EV / EBITDA	-0.80×
EV / Sales	1.37×
Earnings Yield	-30799.72%
Free Cash Flow Yield	-1735.39%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$161.36M
Revenue (TTM)	$117.63M
Net Income (TTM)	-$252.87M
Free Cash Flow (TTM)	$12.69M
Net Debt	$160.54M
Working Capital	-$152.98M
Gross Margin	60.86%
Operating Margin	-19.78%
Net Margin	-214.95%
Return on Equity	786.07%
Return on Invested Capital	-25.57%